Floctafenine, a nonsteroidal anti-inflammatory agent (NSAID), acts as an effective analgesic agent. Floctafenine is an inhibitor of COX-1 and COX-2 activities in vitro,showing a slightly higher potency towards COX-I. Floctafenine is used for the research of short term pain treatment.

Product information

CAS Number: 23779-99-9

Molecular Weight: 406.36

Formula: C20H17F3N2O4

Chemical Name: 2,3-dihydroxypropyl 2-{[8-(trifluoromethyl)quinolin-4-yl]amino}benzoate

Smiles: OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2C1=CC=CC=2C(F)(F)F

InChiKey: APQPGQGAWABJLN-UHFFFAOYSA-N

InChi: InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Floctafenine (0.1-100 μM; in the presence of LPS; 24 hours) is slightly more potent 1.5-fold to inhibit in vitro platelet COX-I than monocyte COX-2. The IC50 values for platelet COX-I and monocyte COX-2 inhibition are 2.33 μM (95%CI) and 3.47 μM (95%CI), respectively in heparinized whole blood samples. Floctafenine (0.1-100 μM; in the presence of A23187; 1 hour) does not significantly affect A23187-caused LTB4 generation even up to 100 μM.

In Vivo:

Floctafenine (intraperitoneal injection; 50 mg/kg; single dose; 30 minutes prior to p-benzoquinone) has an inhibitory effects on p-benoquinone-induced writhing in rats, inhibition of writhing is 65.98%.

Products are for research use only. Not for human use.